Literature DB >> 22218514

Incidence and risk factors of immune reconstitution inflammatory syndrome in HIV-TB coinfected patients.

De Dibyendu1, Rathindra Nath Sarkar, Sibaji Phaujdar, Kuntal Bhattacharyya, Hare Krishna Pal.   

Abstract

UNLABELLED: Tuberculosis is one of the leading causes of development of Immune reconstitution inflammatory syndrome (IRIS) in HIV patients receiving antiretroviral therapy (ART).
OBJECTIVE: To determine the incidence of IRIS in HIV-TB coinfected patients, and to find out the possible risk factors associated with IRIS.
MATERIALS AND METHODS: Study commenced with 96 patients adhered to standard antitubercular therapy (ATT) and ART without defaulting, and followed up for six months. RESULT: The mean (± SD) CD4 count and CD4 percentage at baseline was 59.16 (± 24.63) per mm³ and 4.59% (± 1.73) respectively. Only 18.75% developed IRIS after 57.05 (± 14.12) days of initiation of ART. Extrapulmonary tuberculosis was the most significant factor associated with IRIS (83.33%) than those without IRIS (44.87%) (p = 0.0032). Specifically, tubercular lymphadenitis (38.88%, p = 0.0364) and disseminated tuberculosis (33.33%, p = 0.0217) were significantly associated with IRIS. The other risk factors associated with appearance of IRIS were higher CD4 count (p = 0.0212) at three months after initiation of ART and increment of CD4 count (p = 0.0063) and CD4 percentage (p = 0.0016) during this period. The major manifestations of IRIS were fever (40%), followed by lymphadenitis (38%). The mortality rate in IRIS was not higher than those without IRIS.
CONCLUSION: Patients with extrapulmonary tuberculosis, especially tubercular lymphadenitis, were more likely to develop IRIS and fever was associated in most of them. Higher increment of CD4 count may indicate development of IRIS in presence of new or worsening tuberculosis lesion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22218514     DOI: 10.1016/s1413-8670(11)70250-1

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  6 in total

1.  The Epidemiology of IRIS in Southern India: An Observational Cohort Study.

Authors:  Nisha Thambuchetty; Kayur Mehta; Karthika Arumugam; Umadevi G Shekarappa; Jyothi Idiculla; Anita Shet
Journal:  J Int Assoc Provid AIDS Care       Date:  2017-04-12

Review 2.  Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease.

Authors:  Carson M Quinn; Victoria Poplin; John Kasibante; Kyle Yuquimpo; Jane Gakuru; Fiona V Cresswell; Nathan C Bahr
Journal:  Life (Basel)       Date:  2020-10-29

3.  Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.

Authors:  Claudia P Cortes; Firas H Wehbe; Catherine C McGowan; Bryan E Shepherd; Stephany N Duda; Cathy A Jenkins; Elsa Gonzalez; Gabriela Carriquiry; Mauro Schechter; Denis Padgett; Carina Cesar; Juan Sierra Madero; Jean W Pape; Daniel R Masys; Timothy R Sterling
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

4.  Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome.

Authors:  Maryline Bonnet; Elisabeth Baudin; Ilesh V Jani; Elizabete Nunes; François Verhoustraten; Alexandra Calmy; Rui Bastos; Nilesh B Bhatt; Christophe Michon
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

5.  Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: a case control study.

Authors:  Colin Stewart Brown; Colette Joanne Smith; Ronan Angus MacCormick Breen; Lawrence Peter Ormerod; Rahul Mittal; Marie Fisk; Heather June Milburn; Nicholas Martin Price; Graham Henry Bothamley; Marc Caeroos Isaac Lipman
Journal:  BMC Infect Dis       Date:  2016-09-06       Impact factor: 3.090

6.  Tuberculosis, human immunodeficiency virus, and the immune reconstitution inflammatory syndrome.

Authors:  A Rapose; S Karande
Journal:  J Postgrad Med       Date:  2017 Oct-Dec       Impact factor: 1.476

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.